These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 35342288)

  • 1. Molnupiravir Does Not Induce Mutagenesis in Host Lung Cells during SARS-CoV-2 Treatment.
    Githaka JM
    Bioinform Biol Insights; 2022; 16():11779322221085077. PubMed ID: 35342288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the mutagenic effects of Molnupiravir and N4-hydroxycytidine in bacterial and mammalian cells by HiFi sequencing.
    Miranda JA; McKinzie PB; Dobrovolsky VN; Revollo JR
    Environ Mol Mutagen; 2022 Aug; 63(7):320-328. PubMed ID: 36181379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19).
    Pagliano P; Sellitto C; Ascione T; Scarpati G; Folliero V; Piazza O; Franci G; Filippelli A; Conti V
    Expert Opin Drug Discov; 2022 Dec; 17(12):1299-1311. PubMed ID: 36508255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molnupiravir (MK-4482) is efficacious against Omicron and other SARS-CoV-2 variants in the Syrian hamster COVID-19 model.
    Rosenke K; Okumura A; Lewis MC; Feldmann F; Meade-White K; Bohler WF; Griffin A; Rosenke R; Shaia C; Jarvis MA; Feldmann H
    bioRxiv; 2022 Feb; ():. PubMed ID: 35233571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences.
    Singla S; Goyal S
    Bull Natl Res Cent; 2022; 46(1):62. PubMed ID: 35287311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Plitidepsin, an inhibitor of the cell elongation factor eEF1a, and molnupiravir an analogue of the ribonucleoside cytidine, two new chemical compounds with intense activity against SARS-CoV-2].
    Reina J
    Rev Esp Quimioter; 2021 Oct; 34(5):402-407. PubMed ID: 33902254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model.
    Johnson DM; Brasel T; Massey S; Garron T; Grimes M; Smith J; Torres M; Wallace S; Villasante-Tezanos A; Beasley DW; Comer JE
    Antiviral Res; 2023 Jan; 209():105492. PubMed ID: 36535309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
    Sheahan TP; Sims AC; Zhou S; Graham RL; Pruijssers AJ; Agostini ML; Leist SR; Schäfer A; Dinnon KH; Stevens LJ; Chappell JD; Lu X; Hughes TM; George AS; Hill CS; Montgomery SA; Brown AJ; Bluemling GR; Natchus MG; Saindane M; Kolykhalov AA; Painter G; Harcourt J; Tamin A; Thornburg NJ; Swanstrom R; Denison MR; Baric RS
    Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32253226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters.
    Abdelnabi R; Maes P; de Jonghe S; Weynand B; Neyts J
    Front Pharmacol; 2022; 13():1072202. PubMed ID: 36605401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells.
    Zhou S; Hill CS; Sarkar S; Tse LV; Woodburn BMD; Schinazi RF; Sheahan TP; Baric RS; Heise MT; Swanstrom R
    J Infect Dis; 2021 Aug; 224(3):415-419. PubMed ID: 33961695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Antiviral Therapy in Highly-Transmissible Variants of SARS-CoV-2: A Modeling and Simulation Study.
    Schöning V; Kern C; Chaccour C; Hammann F
    Front Pharmacol; 2022; 13():816429. PubMed ID: 35222030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.
    Gordon CJ; Tchesnokov EP; Schinazi RF; Götte M
    J Biol Chem; 2021 Jul; 297(1):100770. PubMed ID: 33989635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-Molecule Antiviral β-d-
    Agostini ML; Pruijssers AJ; Chappell JD; Gribble J; Lu X; Andres EL; Bluemling GR; Lockwood MA; Sheahan TP; Sims AC; Natchus MG; Saindane M; Kolykhalov AA; Painter GR; Baric RS; Denison MR
    J Virol; 2019 Dec; 93(24):. PubMed ID: 31578288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.
    Cox RM; Wolf JD; Plemper RK
    Nat Microbiol; 2021 Jan; 6(1):11-18. PubMed ID: 33273742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.
    Menéndez-Arias L
    J Biol Chem; 2021 Jul; 297(1):100867. PubMed ID: 34118236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.
    Lee CC; Hsieh CC; Ko WC
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
    Fischer WA; Eron JJ; Holman W; Cohen MS; Fang L; Szewczyk LJ; Sheahan TP; Baric R; Mollan KR; Wolfe CR; Duke ER; Azizad MM; Borroto-Esoda K; Wohl DA; Coombs RW; James Loftis A; Alabanza P; Lipansky F; Painter WP
    Sci Transl Med; 2022 Jan; 14(628):eabl7430. PubMed ID: 34941423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Molnupiravir and Nirmatrelvir Treatment Improves the Inhibitory Effect on SARS-CoV-2 in Rhesus Macaques.
    Rosenke K; Lewis MC; Feldmann F; Bohrnsen E; Schwarz B; Okumura A; Bohler WF; Callison J; Shaia C; Bosio CM; Lovaglio J; Saturday G; Jarvis MA; Feldmann H
    bioRxiv; 2022 Sep; ():. PubMed ID: 36263071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication.
    Ramirez S; Fernandez-Antunez C; Galli A; Underwood A; Pham LV; Ryberg LA; Feng S; Pedersen MS; Mikkelsen LS; Belouzard S; Dubuisson J; Sølund C; Weis N; Gottwein JM; Fahnøe U; Bukh J
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0009721. PubMed ID: 33903110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of Molnupiravir in COVID-19 patients: a systematic review.
    Mali KR; Eerike M; Raj GM; Bisoi D; Priyadarshini R; Ravi G; Chaliserry LF; Janti SS
    Ir J Med Sci; 2023 Aug; 192(4):1665-1678. PubMed ID: 36087236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.